ClinicalTrials.gg
Not yet recruitingNCT06409286Updated May 15, 2025

Assessment of Flow in Cerebrospinal Fluid Shunts With a Second Generation Wireless Thermal Anisotropy Measurement Device

An observational study in Hydrocephalus, sponsored by Rhaeos, Inc.. Not yet recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2025-05-15.

Sponsored by Rhaeos, Inc. · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
17
Sex
All
01

Study summary

This study evaluates the performance of a thermal anisotropy measurement device for non-invasively assessing CSF shunt flow. Patients with an existing implanted shunt and symptoms of shunt malfunction who require shunt revision surgery will be evaluated with the study device to assess flow in CSF shunts as confirmed by surgical outcomes at 7 days. If successful, this study will show that the study device accurately distinguishes between functioning (flowing) and non-functioning (non-flowing) shunts.

02

Conditions studied

  • Hydrocephalus

Browse trials for

03

In context

Hydrocephalus

190 studies on the registry are indexed under Hydrocephalus; 52 are open to participants now.

This study's planned enrollment of 17 is below the median of 73 across 86 observational studies indexed under Hydrocephalus.

Browse Hydrocephalus studies →

Lead sponsor

Rhaeos, Inc. is the lead sponsor of 16 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pediatric and adult shunt-dependent hydrocephalus patients with an existing ventriculoperitoneal (VP) shunt who are experiencing shunt malfunction symptoms and require shunt revision surgery per standard of care shunt evaluation without use of the study device data will be enrolled in this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Existing ventriculoperitoneal CSF shunt on which the subject is dependent
  2. At least one symptom of shunt malfunction as determined by the investigator, such as but not limited to seizure, fever, headache, vision problems, dizziness, disorientation, confusion, vomiting, lethargy, irritability, difficulty waking or staying awake, swelling along shunt tract, enlargement of head, loss of balance, gait disturbance, and loss of sensory or motor function
  3. Exhibit shunt malfunction symptom(s) requiring surgical shunt revision per standard of care assessment without use of device data
  4. Region of intact skin overlying an unambiguously identifiable chronically indwelling ventricular shunt which crosses the clavicle and is appropriate in size for application of the study device
  5. Available for follow-up for up to seven days
  6. Signed by subject or a parent, legal guardian, health care agent, or surrogate decision maker (according to local statutes, and collectively referred to as "surrogates" in this protocol)

Exclusion criteria

Exclusion Criteria:

  1. Presence of more than one distal shunt catheter in the study device measurement region
  2. Presence of an interfering open wound or edema in the study device measurement area
  3. Subject-reported history of adverse skin reactions to adhesives
  4. Investigator judges that the subject is likely to be lost to follow-up due to unavailability or clinical outcome being unobtainable
  5. Participation in the study will interfere with, or be detrimental to, administration of optimal health-care to the subject
  6. Previous participation in a Rhaeos clinical study in which FlowSense device measurement data were acquired
  7. Participation in any other procedural, pharmaceutical, and/or device study that may influence the collection of valid data under this study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
17 participants (estimated)
Patient registry
No

Groups and cohorts

  • Shunted patients undergoing surgery

    Patients with an existing implanted ventriculoperitoneal shunt who are experiencing shunt malfunction symptoms and require shunt revision surgery per standard of care shunt evaluation

    Device: Thermal Anisotropy Measurement Device

Interventions

  • DeviceThermal Anisotropy Measurement Device

    A wireless device for non-invasively assessing CSF shunt flow

    Also known as: FlowSense

06

What researchers measure

Primary outcomes

  1. Flowsense Sensitivity

    The study device will yield an output of either "flow confirmed" or "flow not confirmed." Based on this assessment and the standard-of-care clinical treatment, each subject will fall into one of the following categories: True Positive (TP): Device outputs "flow not confirmed" AND a shunt revision surgery with confirmed shunt failure is performed False Positive (FP): Device outputs "flow not confirmed" AND either no shunt revision surgery is performed for 7 days or a shunt revision surgery without a confirmed shunt failure is performed True Negative (TN): Device outputs "flow confirmed" AND either no shunt revision surgery is performed for 7 days or a shunt revision surgery without a confirmed shunt failure is performed False Negative (FN): Device outputs "flow confirmed" AND a shunt revision surgery with confirmed shunt failure is performed Study device sensitivity will be calculated as TP / (TP + FN).

    Time frame: Upto 7 days

Secondary outcomes

  1. Study device specificity, diagnostic accuracy, positive predictive value (PPV), negative predictive value (NPV), and diagnostic performance

    These secondary endpoints do not have associated success criteria. The study is not powered to achieve statistical significance for these endpoints.

    Time frame: Up to 7 days

07

Study locations

1 site
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06409286
Lead sponsor
Rhaeos, Inc.
Responsible party
Sponsor
First posted
May 10, 2024
Start date
Jul 2025 (estimated)
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
May 15, 2025

Study contacts

Anna Lisa Somera
Contact
info@rhaeos.com
855-814-3569

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion